Circulate Health is building a patient-centered platform that applies advanced therapeutic plasma exchange (TPE) to filter circulating microplastics, environmental toxins, and other inflammatory agents from the bloodstream. The company positions its solution as a science-backed approach to proactive longevity care, addressing systemic inflammation and oxidative stress linked to aging and chronic disease. Backed by Khosla Ventures, Circulate Health has gained early traction within the growing consumer interest in longevity treatments. CEO and co-founder Brad Younggren notes the company is experiencing strong momentum and will use fresh capital to enhance research and expand its platform. By targeting a scalable delivery model for TPE, Circulate Health aims to make the procedure more accessible to a wider population. The firm emphasizes its role at the “center” of the convergence between precision health and preventative wellness. No operating metrics such as revenue or user counts were disclosed in the announcement.

Total raised

$12M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2025